Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1982 1
1983 1
1986 1
1990 1
1995 1
2005 1
2007 1
2010 1
2014 1
2018 2
2019 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Amato AA, et al. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. Neurology. 2021. PMID: 33597289 Free PMC article. Clinical Trial.
OBJECTIVE: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). ...Overall, 91.0% (n = 142) of participants in the pooled bimagrumab group and 89.1% (n = 49) in the placebo group had 1 treatment-emergent adver …
OBJECTIVE: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). ...Overa …
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register.
Mannucci PM, Nobili A, Pasina L; REPOSI Collaborators (REPOSI is the acronym of REgistro POliterapie SIMI, Società Italiana di Medicina Interna). Mannucci PM, et al. Intern Emerg Med. 2018 Dec;13(8):1191-1200. doi: 10.1007/s11739-018-1941-8. Epub 2018 Aug 31. Intern Emerg Med. 2018. PMID: 30171585 Review.
Polypharmacy (defined as the chronic intake of five or more drugs) is associated with increased risks of drug-drug interactions and related adverse effects, prescription and intake errors, poor compliance, re-hospitalization and mortality. ...The main findings of th …
Polypharmacy (defined as the chronic intake of five or more drugs) is associated with increased risks of drug-drug interactions and related …
Osteopontin overexpression inhibits in vitro re-endothelialization via integrin engagement.
Leali D, Moroni E, Bussolino F, Presta M. Leali D, et al. J Biol Chem. 2007 Jul 6;282(27):19676-84. doi: 10.1074/jbc.M606938200. Epub 2007 Apr 23. J Biol Chem. 2007. PMID: 17456474 Free article.
In conclusion, OPN up-regulation impairs re-endothelialization by inhibiting the first phase of the cell migration cycle via alpha(v) integrin engagement by the extracellular matrix-immobilized protein. This may contribute to the adverse effects exerted by OPN in re …
In conclusion, OPN up-regulation impairs re-endothelialization by inhibiting the first phase of the cell migration cycle via alpha(v) integr …
Target cells for GM-CSF and kinetics of response.
Aglietta M, Bussolino F, Piacibello W, Aprá F, Sanavio F, Stacchini A, Monzeglio C, Carnino F, Stern AC, Gavosto F. Aglietta M, et al. Prog Clin Biol Res. 1990;352:519-30. Prog Clin Biol Res. 1990. PMID: 2169636 Review. No abstract available.
Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study.
Pasina L, Brignolo Ottolini B, Cortesi L, Tettamanti M, Franchi C, Marengoni A, Mannucci PM, Nobili A; REPOSI Investigators. Pasina L, et al. Med Princ Pract. 2019;28(6):501-508. doi: 10.1159/000499692. Epub 2019 Mar 20. Med Princ Pract. 2019. PMID: 30889568 Free PMC article.
OBJECTIVE: Older people approaching the end of life are at a high risk for adverse drug reactions. Approaching the end of life should change the therapeutic aims, triggering a reduction in the number of drugs.The main aim of this study is to describe the preventive and sym …
OBJECTIVE: Older people approaching the end of life are at a high risk for adverse drug reactions. Approaching the end of life should …
[Substance dependence and pregnancy. Experience in care].
Bussolino S, Tibaldi C, Mansueto MG, Todros T, Geda O, Sanfelici C, Gagliardi L. Bussolino S, et al. Minerva Ginecol. 1986 Nov;38(11):895-902. Minerva Ginecol. 1986. PMID: 3808423 Italian. No abstract available.
16 results